Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.CD-NB2016-165. Epub 2017 Jan 11.
Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease progression due to activation loop mutations, which are resistant to approved drugs. However, phase I trials suggest that the cancer is sensitive to two new agents: BLU-285 and DCC-2618. In addition, liquid biopsies, which were used to follow patients during the trials, may be valuable tools in tracking disease progression and assessing tumor heterogeneity.
酪氨酸激酶抑制剂最初可能控制胃肠道间质肿瘤，但由于激活环突变，大多数患者最终会出现疾病进展，而这些突变对已批准的药物具有抗性。然而，I 期临床试验表明，这两种新药物：BLU-285 和 DCC-2618 对癌症敏感。此外，在试验期间用于监测患者的液体活检可能是跟踪疾病进展和评估肿瘤异质性的有价值的工具。
